— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
CVS Health Corporation (NYSE: CVS) reported record full-year 2025 consolidated revenues of $402.1 billion, a…
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues…
The industrial materials manufacturer reported flat fourth-quarter sales and a full-year organic growth rate of…
Overview Harley-Davidson, Inc. reported consolidated fourth-quarter 2025 results that point to continued pressure on profitability…
The Coca-Cola Company (NYSE: KO) reported its fourth quarter 2025 earnings results today. Net revenues…
The South Korean telecommunications provider reported a significant increase in annual profit for 2025, supported…